PARP and PARG inhibitors--new therapeutic targets in cancer treatment.

Nilufer Jasmine Selimah Fauzee, Juan Pan, Ya-lan Wang

Department of Pathology, Molecular Medicine and Cancer Research Center, Chongqing Medical University, Chongqing 400016, China.

Pathology oncology research : POR 2010 Dec

filter terms:

Today, the number of cancer patients throughout the world is increasing alarmingly and as per the World Health Organisation (WHO) data and statistics the prediction for the year 2020 will be 15 million new cases as compared to only 10 million cases in year 2000 leaving us dumbfounded. A lot of effort has been put in by researchers and scientists over decades to find drugs helpful in the treatment of cancers for the benefit of patients--the latest being the Poly ADP-ribose polymerase (PARP) and the Poly ADP-ribose glycohydrolase (PARG) inhibitors. This review highlights their mechanism of action under the rationale of their use and current development in the field of cancer.

Citation

Nilufer Jasmine Selimah Fauzee, Juan Pan, Ya-lan Wang. PARP and PARG inhibitors--new therapeutic targets in cancer treatment. Pathology oncology research : POR. 2010 Dec;16(4):469-78